source
- STAT+: For prostate cancer patients set on surgery, new hormone regimen may improve outcomes, study findsBy doing hormone therapy upfront in prostate cancer cases, the hope was to shrink the relapse rate after surgery. Results were encouraging.STAT · 2mo ago↗ source
- Akeso, Summit drug extends survival in closely watched lung cancer trialThough ivonescimab reduced the risk of death by one-third compared to chemotherapy in a China-based study, the total survival benefit of four months stirred debate and pressured company shares.BioPharma Dive · 2mo ago↗ source
- ‘Unprecedented’ Revolution data point to paradigm shift in pancreatic cancerHighly anticipated data presented at ASCO confirmed what’s been heralded as a medical breakthrough against a historically tough-to-treat tumor.